METHYLTESTOSTERONE

Post-LOE

methyltestosterone

Merck & Co.

ANDAORALCAPSULE

Approved

Feb 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

METHYLTESTOSTERONE (methyltestosterone) by Merck & Co. is androgen receptor agonists [moa]. Approved for the: treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. First approved in 2022.

Drug data last refreshed 20h ago

Mechanism of Action

Androgen Receptor Agonists

Pharmacologic Class:

Androgen

Indications (1)

the: Treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone

Company

Worked on METHYLTESTOSTERONE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.